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Abstract
Background: Retention rate, efficacy, and safety of abatacept (ABA) was compared between patients with rheumatoid
arthritis receiving ABA as monotherapy to those in combination ABA + conventional synthetic DMARD (csDMARD).
Methods: The patients were obtained from the ORA registry. The retention rate was analysed in two ways:
(1) therapeutic strategy retention, in which the addition of a csDMARD was considered to indicate failure of the
monotherapy strategy; and (2) ABA retention, which was assessed by the discontinuation of ABA regardless of
other treatment modifications. Efficacy and safety were compared between ABA initiated alone and ABA used in
combination with a csDMARD.
Results: The retention rate at month 6 (M6) was evaluated in 569 patients. A significant difference was identified in the
retention rate between the ABA monotherapy strategy and the ABA + csDMARD strategy (58.5 % [110/188] vs. 68 %
[258/381], respectively, p = 0.031). No significant difference was identified in the ABA retention rate initiated either as a
monotherapy or in combination with csDMARDs (75 % [142/188] vs. 76 % [291/381], respectively, p = 0.824). Data
regarding ABA efficacy were available for 444 patients. There was no significant difference in the responder proportion
after 6 months of treatment between ABA monotherapy and ABA + csDMARD treatment (60.2 % [88/146] vs. 60 %
[179/298], respectively, p = 0.967).
Conclusions: This “real-life” analysis, which is relevant for bedside practice, emphasised the satisfactory efficacy and
safety of ABA used in monotherapy, which provides an acceptable alternative when csDMARDs are undesirable.
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Background
In parallel with the discovery of new pathways and drugs
in the pathogenesis of rheumatoid arthritis (RA), the de-
velopment of new therapeutic strategies has been a key
component in the improvement of RA care [1]. These
strategies include the early introduction of disease-
modifying anti-rheumatic drugs (DMARDs), treat to tar-
get and tight control [2, 3]. The latter gathers principles
based on the rapid and sustainable control of inflam-
mation by optimised treatments. The combination of
methotrexate (MTX) and a biologic agent is considered
as the standard strategy for RA that is responding poorly
to conventional synthetic DMARDs (csDMARDs) alone.
This has been recently disputed by an increasing
number of studies, where combinations of synthetic
DMARDs are non-inferior to combination biological
DMARDs (bDMARDs) and synthetic DMARDs [4].
Since the earliest studies conducted with tumour necro-
sis factor alpha (TNF-α) inhibitors, it has been demon-
strated that the therapeutic response to biological agents
was improved by the addition of a csDMARD, primarily
MTX [5, 6]. Subsequently, most clinical trials have eval-
uated bDMARDs in combination with MTX. However,
MTX is sometimes contraindicated; it is also responsible
for minor but bothersome side effects. Moreover, many
patients do not understand why they must continue a
treatment that has previously failed to improve their
condition. As a consequence, all bDMARD registries
have indicated that these agents are used in monother-
apy in one-third of patients in daily practice [7]. Re-
cently, the AMBITION and ACT-RAY studies discussed
the equivalence of tocilizumab when used in monother-
apy or in combination with MTX [8, 9].
Association with MTX is required by the French and
European marketing authorisation for abatacept (ABA).
Very few data are available regarding the use of ABA in
intravenous monotherapy apart from the very recently
published AVERT trial [10].
In the present study, we analysed data from the
Orencia and Rheumatoid Arthritis (ORA) registry to
compare ABA monotherapy with an ABA + csDMARD
combined strategy, using the retention rate as the princi-
pal outcome. This study provides the first evaluation of




The ORA registry is an ongoing, nationwide, prospective
French cohort study that investigates the long-term
safety and efficacy of ABA in the treatment of RA. It
was established in June 2008 by the French Society of
Rheumatology upon the drug’s approval for use in
France [11]. The last patient in that study was included
in the ORA registry in 2010. The ORA registry received
approval from the French authorities and patients were
included after written informed consent was obtained.
Data at baseline, month 3 (M3) and month 6 (M6)
were collected by trained clinical nurses or techni-
cians in each centre.
Population
Inclusion criteria
All patients from the ORA registry who had previously
completed their 6-month follow-up visit were included
in our study.
Exclusion criteria
A lower age limit of 18 years old was established, and pa-
tients with outliers among their data were excluded from
the study. Patients who did not meet the 1987 American
College of Rheumatology (ACR) criteria (primarily due to
missing or inconsistent data in the registry) were excluded
from the study.
Definitions of treatment groups
The patients were retrospectively assigned to two main
groups according to the initiation of either ABA alone
or ABA in combination with a csDMARD. In each
group, two analyses were performed according to the
initial treatment conditions (Fig. 1).
First, patients initially treated with ABA as a monother-
apy, regardless of whether a csDMARD was secondarily
Fig. 1 Groups of patients for retention rate calculations. Patients of
the ORA registry were assigned retrospectively to two main groups.
a Patients treated with ABA initiated as a monotherapy. In a first
analysis, we considered patients for whom ABA was maintained
as a monotherapy (MonoABA). In a second analysis, we considered
all patients of this group regardless of whether a csDMARD was
secondarily added (StartMONO). b Patients treated with ABA initiated
in combination with a csDMARD. In a first analysis, we considered
patients for whom ABA was maintained as a combination therapy
with a csDMARD (CombiABA). In a second analysis, we considered all
patients of this group regardless of whether the csDMARD was
secondarily withdrawn (StartCOMBI). ABA abatacept, csDMARD
conventional synthetic disease-modifying anti-rheumatic drug,
M0 month 0, M6month 6, ORA Orencia and Rheumatoid Arthritis
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added during the 6-month period of analysis were named
StartMONO. A subset of this group continued ABA as a
monotherapy throughout the 6-month period of analysis
(MonoABA).
Second, patients initially treated with ABA in com-
bination with a csDMARD, regardless of whether the
csDMARD was continued or withdrawn during the
6-month period of analysis were named StartCOMBI. A
subset of this group continued ABA in combination with
a csDMARD throughout the 6-month period of analysis
(CombiABA).
Patients in MonoABA and CombiABA are also in-
cluded in StartMONO and StartCOMBI, respectively.
Assessment criteria and objectives
We assessed as the principal objective the retention of a
treatment strategy (MonoABA vs. CombiABA) during
the 6-month period, wherein a patient is treated in the
same manner from the start to the end of follow-up.
Secondary objectives comprised the retention of ABA
itself in StartMONO vs. StartCOMBI groups during the
6-month period observed. We also evaluated the efficacy
in MonoABA vs. CombiABA and in StartMONO vs. Start-
COMBI groups, assessed by the 28-item Disease Activity
Score (DAS-28) erythrocyte sedimentation rate (ESR) score
at month 0 (M0) and month 6 (M6). According to the
European League Against Rheumatism (EULAR) criteria,
treatment was considered effective when the EULAR
response was good or moderate. The administration of
corticosteroids was observed in the StartMONO and
StartCOMBI groups. Finally, safety in the StartMONO and
StartCOMBI groups, defined as the number of patients
with at least one mild (clinical observation only without
any intervention indicated), moderate (minimal interven-
tion needed) or severe (hospitalization, and/or intravenous
treatment required and/or resulting in death) adverse event
during the 6-month period was assessed.
Statistical analysis
Statistical analysis was performed using the STATA/SE soft-
ware, version 13.1 (College Station, TX, USA: StataCorp
LP). Appropriate testing was performed according to the
results of normality tests. Student’s t test and the Mann-
Whitney test (or Wilcoxon’s test for paired values) were
used to analyse quantitative data, and the chi-square or
Fisher’s exact test was used to analyse qualitative data. A
p value <0.05 was considered statistically significant.
Results
Baseline demographics and characteristics of the
population
Of the 1032 patients included in the ORA registry,
829 (80.3 %) had been followed for at least 6 months at
the time of analysis. Of these 829 patients, 276 (33.3 %)
received ABA as a monotherapy at M0. A flow chart of
the patient exclusion strategy is shown in Fig. 2. Exclu-
sions were primarily due to missing data. The median age
and disease duration were 60 (range: 20–89) and 14
(range: 2–51) years, respectively. The patients with fully
available data for analysis were 90 % positive for anti-
citrullinated protein antibodies (for a 70.9 % in the whole
registry) [12]. ABA was administered as the first biological
treatment in 12 % of the patients. One anti-TNF agent
was used prior to ABA in 24 % of the patients, two agents
in 40 % of the patients, and three agents in approximately
24 % of the patients. The clinical and biological charac-
teristics were comparable between the StartMONO and
StartCombi groups (Table 1).
ABA retention rate
Drug withdrawal or treatment modifications are indirect
indicators of safety and efficacy and are fairly well repre-
sented by the retention rate [13]. No survival curve was
performed because of too short a duration of follow-up
(6 months) and of the small number of intermediate sur-
veys. Of the 829 patients with complete follow-ups, data
were fully available for 569 concerning the retention
Fig. 2 Flow chart illustrating the patient inclusion protocol for the
study. Patients were excluded if their data consisted of outliers (n = 12)
or contained errors in the collection process. Missing data constituted
the main explanation for patient exclusion. At a minimum, treatment
information at months 0 and 6 was required for inclusion
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rate. At M0, 188 of these 569 patients initiated ABA as a
monotherapy (StartMONO), and 381 patients initiated
ABA in combination with a csDMARD (StartCOMBI).
MonoABA vs. CombiABA
In a first analysis, any changes in the ABA or csDMARD
regimen were considered to represent a failure of the
treatment strategy. We identified a significantly lower
retention rate of the MonoABA group compared with the
CombiABA group (58.5 % [110/188] vs. 68 % [258/381],
p = 0.031). Seventy-eight patients failed to maintain
abatacept in monotherapy, amongst whom 46 stopped the
abatacept and 32 started a DMARD in complement.
Furthermore, a significantly increased risk of strategy
discontinuation was identified for the MonoABA group
compared with the CombiABA group (relative risk [RR]:
1.48; 95 % confidence interval [CI]: 1.02–2.17).
StartMONO vs. StartCOMBI
In the second analysis, ABA retention rate was con-
sidered regardless of whether csDMARD treatment was
added or stopped. We found that the ABA retention rate
was similar in both the StartMONO and StartCOMBI
groups (75 % [142/188] vs. 76 % [291/381], respectively,
p = 0.824).
Reasons for ABA monotherapy discontinuation
We compared the reasons for ABA discontinuation in the
entire sample population. The most common explanation
for the termination of ABA treatment was primary
ineffectiveness, with a comparable incidence in both the
StartMONO and StartCOMBI groups (41.3 % in the Start-
MONO group vs. 44.4 % in the StartCOMBI group,
p = 0.709). The distribution of other reasons for the
discontinuation of ABA infusion was also comparable
between the two groups and is shown in Table 2.
Therapeutic escape was considered when primary efficacy
was observed at M3 and not at M6.
Efficacy
MonoABA vs. CombiABA
In the MonoABA (n = 110) and CombiABA (n = 258)
groups, data for the evaluation of the EULAR response
were available for 99 and 223 patients, respectively. The
efficacy of these strategies at M6 was similar in both
groups, with 70.7 % (70/99) good or moderate re-
sponders in the MonoABA group vs. 67.7 % (151/223)
in the CombiABA group (p = 0.592).
StartMONO vs. StartCOMBI
The necessary data to determine efficacy were available
for 444 patients. The efficacy of ABA at M6 was similar
in both groups, with approximately 60 % good or mod-
erate EULAR responses in the treated patients: 60.2 %
(88/146) in the StartMONO group vs. 60 % (179/298) in
the StartCOMBI group (p = 0.967).
Corticosteroids
Corticosteroids were frequently co-administered with
ABA in RA in general and in the ORA registry in par-
ticular. Increases in corticosteroid dosage could reflect
the poor effectiveness of DMARDs, whereas corticos-
teroid tapering or withdrawal might attest to DMARD
efficacy. Data regarding the corticosteroid doses at M0
and M6 were available for 323 patients. The frequency
of patients who required an increase in corticosteroid
dose was equivalent between the StartMONO and
Table 1 Clinical features of the 569 patients registered in the







Sex, female n (%) 153 (81 %) 297 (78 %)
Age, median (range) 63 (22–89) 59 (23–89)
Duration of disease,
median (range)
16 (3–51) 14 (2–45)
Inclusion DAS-28 score,
median (range)
5.5 (2–8.9) 5.3 (1.6–8.5)
Previous anti-TNF therapy,
n (%)
0 26 (14 %) 38 (10 %)
1 47 (25 %) 85 (22 %)
2 72 (38 %) 156 (41 %)
3 43 (23 %) 102 (27 %)
Previous rituximab therapy,
n (%)
72 (38 %) 104 (27 %)
Cortisone treatment, n (%) 144 (75 %) 280 (73 %)
Rheumatoid factor, n (%) 73/86 (85 %) 133/155 (86 %)
ACPA, n (%) 67/71 (94 %) 112/124 (90 %)
C-reactive protein,
median (range)
14 (0.2–157) 12 (0–179)
Smoking, n (%) 18 (9 %) 49 (13 %)
DMARDs disease-modifying anti-rheumatic drugs, DAS-28 28-item Disease
Activity Score, TNF tumour necrosis factor, ACPA anti-citrullinated peptide antibody
Table 2 Reasons for discontinuation of abatacept infusion in







DMARD (n = 90)
Primary ineffectiveness, n (%) 19 (41.3 %) 40 (44.4 %)
Therapeutic escape, n (%) 3 (6.6 %) 9 (10 %)
Infusion reaction, n (%) 2 (4.3 %) 1 (1.1 %)
Other side effects, n (%) 4 (8.7 %) 6 (6.7 %)
Unknown, n (%) 18 (39.1 %) 34 (37.8 %)
DMARDs disease-modifying anti-rheumatic drugs
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StartCOMBI groups (10/98 patients (10.2 %) vs. 28/225
patients (12.4 %), respectively, p = 0.566). In addition, an
equivalent reduction in the corticosteroid dose was
identified in both groups (-3.31 ± 7.94 in StartMONO
and -2.44 ± 5.59 in StartCOMBI, p = 0.25).
Safety
In terms of safety, the main reason to discontinue ABA
treatment was the occurrence of infusion reactions.
There were no significant differences between the
StartMONO and StartCOMBI groups regarding the inci-
dence of infusion reactions (4.3 % vs. 1.1 %, respectively,
p = 0.22) or frequency of other side effects (8.7 % vs.
6.7 %, respectively, p = 0.67).
In terms of serious adverse events, the incidence of
cancers was not significantly different between the
StartMONO and StartCOMBI groups (3.7 % vs. 3.4 %,
p = 0.850), and there was no predominance of a particular
type of cancer.
The global incidence of infections was not significantly
different between the groups (12.2 % vs. 10.7 %, p = 0.0601).
Unfortunately, we could not distinguish these events as
minor or severe infections because of a lack of precision
in the collected data.
Liver function tests were available for 438 patients. No
significant difference was identified between the Start-
MONO and StartCOMBI groups in terms of liver abnor-
malities (18.9 % [29/153] vs. 14 % [40/285], respectively,
p = 0.178).
Discussion
Based on the analysis of ORA registry data, this study
demonstrated that the ABA monotherapy strategy had a
lower retention rate compared with the combination
strategy, with an estimated relative risk of failure of 1.48.
In addition, the ABA molecule had a similar retention
rate at 6 months, regardless of whether the ABA treat-
ment was initiated as a monotherapy or in combination
with a csDMARD. Finally, efficacy and safety were com-
parable amongst all treatment groups, even if we have
no information on efficacy in the subgroup of Start-
MONO patients who secondarily initiated a DMARD.
The results suggested that the combination strategy was
more successful than the monotherapy strategy in term
of maintenance. However those that were successful on
monotherapy showed equivalent efficacy, whilst in those
requiring treatment adjustments, comparable retention
and response could be achieved.
The use of registries offers the great benefit of analys-
ing real-life data from non-selected patients, without the
constraints of physician prescriptions. However, our
study had some limitations. One major limitation was
the short follow-up period, which was restricted to
6 months. This follow-up time is too short for a survival
analysis. Six months is not a long enough observational
period to draw definitive conclusions about the drug sur-
vival. Nevertheless, this period of follow-up corresponds
to daily practice: often, a 6-month period is routinely
necessary to assess a DMARD’s efficacy. Nevertheless, a
long-term analysis of the ORA data would be interesting
to complete our study. We chose the treatment retention
rate as the main criterion for the global assessment of effi-
cacy, because of the frequently missing data for the calcu-
lation of the DAS-28. A drug maintenance rate reflects
the effectiveness, safety, acceptance and tolerability of a
medication, and it appears to be a good criterion for drug
evaluation in daily practice. Another limitation implied by
this short follow-up time was that we could not consider
the structural progression within the 6-month period. Our
study is limited by the high number of patients with miss-
ing data of ABA retention is very high. The lack of data is
explained by the number of patients who did not complete
the 6-month visit at the time of the end of our study and
by the missing data due to patients lost to follow-up.
These caveats are usually found in registry observa-
tional studies.
The monotherapy issue is of great relevance, as one-
third of patients are treated with monotherapy in daily
practice and registries, regardless of the reason, i.e. real
contraindications for synthetic DMARDs, patient prefer-
ence or compliance [5–7]. In addition, some patients do
not understand why they are maintained on treatments
that previously failed to control their disease [14]. A de-
finitive discontinuation of MTX because of intolerance
was reported in 10.5 % of treated patients in a systematic
analysis of the literature [15].
Nonetheless, clinical trials have established that the
therapeutic effects of most biological agents are superior
when used in combination with MTX rather than as
monotherapies [16]. Efficacy of combined treatments
(csDMARD + bDMARD) and even superiority of the
combination over monotherapy was demonstrated very
early for TNF-α blockers [5–10, 17–23]. The results
have been more equivocal for tocilizumab monotherapy.
The AMBITION and ADACTA trials indicated the
superior efficacy of tocilizumab over MTX and adali-
mumab monotherapies, respectively [8, 11, 24]. In the
ACT-RAY trial, a comparison of tocilizumab +MTX
with tocilizumab alone in RA patients with an inad-
equate response to MTX found no significant difference
between the groups in clinical efficacy at week 52 [9].
However, a difference was identified in the percentage of
patients with non-significant radiographic progression:
92.8 % in the combination group vs. 86.1 % in the toci-
lizumab monotherapy group (p = 0.016) [25].
Very few data are available regarding ABA monother-
apy. Immunogenicity of ABA has been shown to be very
low [26]. The ACCOMPANY open-label trial assessed
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the immunogenicity, safety and efficacy of subcutaneous
ABA administered with or without MTX [27]. The main
result of that study was the weak immunogenicity of
ABA, either as a monotherapy or in combination with
MTX, wherein few patients developed anti-drug anti-
bodies; these findings suggest that monotherapy could be
an interesting option for this molecule. No differences
were identified between the groups in clinical efficacy or
safety. The AVERT trial compared ABA, ABA +MTX or
MTX in early and severe RA patients. The combination of
ABA +MTX demonstrated greater efficacy than either
MTX or ABA alone, with 60.9 % of patients achieving
DAS-28 remission at 1 year in the ABA +MTX group
compared with 45.2 % and 42.5 % in the MTX and ABA
monotherapy groups, respectively. Safety was comparable
amongst all treatment groups [10]. Thus, these two trials
led to divergent results, which might be explained by
important differences in methodology: an open-label trial
vs. a randomised, double-blind study, as well as different
patient sample sizes and inclusion criteria.
These results are reinforced by a recent network meta-
analysis that evaluated the comparative effects of bio-
logics as monotherapies and biologics in combination
with MTX on patient-reported outcomes (PROs) [28].
The meta-analysis concluded that, in patients who
inadequately respond to csDMARDs, the efficacies of a
TNF-α inhibitor, ABA, and tocilizumab combined with
MTX were comparable. In contrast, tocilizumab as a
monotherapy was associated with an increased improve-
ment in pain and PROs compared with TNF-α inhibi-
tors. ABA as a monotherapy was not evaluated in the
meta-analysis.
Data obtained from clinical trials do not reflect daily
life for many reasons, including the selection criteria for
patients and the lack of adaptation of the treatment ac-
cording to patient response. In the STURE registry, it
was noted as early as 2003 that patients treated with eta-
nercept +MTX obtained a significantly lower DAS-28
score than patients who received etanercept alone [29].
In the BSR biologic registry, a better response to TNF-α
inhibitors was associated with the concomitant use of
MTX, although statistical significance was only reached
for etanercept (odds ratio [OR] = 1.82, 95 CI: 1.38–2.40)
[30]. In the DANBIO registry, the combination of MTX
with TNF-α inhibitors was associated with fewer drug
withdrawals and a greater proportion of good EULAR
responses [31]. Data from the same Danish registry was
recently analysed for monotherapy use of biologics with
very little information on ABA. The overall conclusion
was that one biologic agent in five was used in mono-
therapy with a remission rate and drug adherence
equivalent except for infliximab. No direct comparison
with combination with csDMARD was made [32]. In a
retrospective analysis of a cohort of patients who were
first administered a TNF-α inhibitor, the switching rate
was significantly increased when the drug was taken as a
monotherapy than when it was used in combination
with MTX [33]. In a Japanese registry, an increased
incidence of discontinuation because of insufficient
efficacy was identified in patients who received etaner-
cept treatment without concomitant MTX (hazard ratio
[HR] = 2.226, 95 % CI 1.363–3.634) [34].
For non-TNF-related biologics, to our knowledge,
there has been only one real-life report of an analysis of
the effect of MTX co-administration, which concerned
both tocilizumab and ABA [35]. In that study, concomi-
tant MTX was not predictive of a better response for
either tocilizumab or ABA. However, only approximately
50 % of the patients used concomitant MTX in the
Danish registry, and there were no precise data re-
garding the persistence of MTX combination over the
study period.
Conclusions
In conclusion, our study suggested that the combination
strategy was more successful than the monotherapy strat-
egy in term of retention. However, patients successful on
monotherapy showed equivalent efficacy, whilst in those
requiring treatment adjustments, comparable retention
and response could be achieved. The lack of structural
data and the short follow-up temper our conclusions, and
this topic should be explored in an analysis involving a
longer period.
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